Preliminary Study on the Characteristic of Plasma Cytokine Profiles in Patients with Idiopathic Multicentric Castleman Diseases.
- Author:
Ning MA
1
;
Hui-Hui LIU
1
;
Wei LIU
1
;
Yue YIN
1
;
Li-Hong WANG
1
;
Ze-Yin LIANG
1
;
Wei-Lin XU
1
;
Qian WANG
1
;
Yuan LI
1
;
Mang-Ju WANG
1
;
Jin-Ping OU
1
;
Wen-Sheng WANG
1
;
Xi-Nan CEN
1
;
Han-Yun REN
1
;
Yu-Jun DONG
2
Author Information
- Publication Type:Journal Article
- MeSH: Castleman Disease; Cytokines; Humans; Interleukin-12; Interleukin-1beta; Plasma
- From: Journal of Experimental Hematology 2019;27(4):1305-1310
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the characteristic changes of the plasma cytokine profile in Chinese patients with idiopathic multicentric Castleman diseases (iMCD).
METHODS:The plasma samples from 22 patients with confirmed diagnosis of iMCD were collected before treatments; Specimens from 17 patients with newly diagnosed multiple myeloma, 10 non Hodgkin's lymphoma, and 15 healthy donors were used as control. Seventeen kinds of cytokines were measured by cytokine beads array (CBA) and ELISA respectively.
RESULTS:Six cytokines were measured by ELISA. The concentrations of IL-2, IL-6, IL-21 and VEGF were significantly higher in the plasma of iMCD patients than those of the healthy donors (P＜0.01) and the level of IL-21 was highest in the iMCD group. There was no significant difference in the levels of IL-1β and IL-4 between the iMCD and healthy donor groups. Thirteen cytokines were measured by CBA assay, besides IL-6 level was confirmed to be higher in iMCD group than that in healthy controls (P＜0.01）, IL-12-p70 and IL-33 levels were also higher in iMCD group than those in control group (P＜0.05）, no significant difference of the rest cytokines was found between iMCD and the control group.
CONCLUSION:IL-6 and VEGF has shown to involved in the pathogenesis of iMCD, the results of preliminary study imply the role of IL-2 、IL-21、IL-12-p70 and IL-33 in this rare lymphoproliferative disease. Further studies are needed to elucidate the mechanism of these cytokines, which may shed some light on the identification of novel therapeutic targets against iMCD.
